The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...

Nordic Bioscience subsidiary KeyBioscience has announced an extension of its strategic partnership with Eli Lilly, focusing ...

Eli Lilly’s shares have surged 750 per cent over five years. Novo Nordisk’s are up about 360 per cent in the same period.

Eli Lilly & Co. is ramping up its legal campaign against companies that were temporarily allowed to make and sell copycat ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

Eli Lilly (NYSE:LLY) has expanded its ongoing collaboration with Swiss biotech KeyBioscience in a bid to obtain global rights ...

A group representing makers of compounded drugs sued FDA over its decision to call an end to the shortage of Lilly's (LLY) ...

A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly’s ...

A group representing companies that made copycat versions of Eli Lilly & Co.’s weight-loss drugs sued the US Food and Drug ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its ...